Activest Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$166 Sell
3
-11
-79% -$594 ﹤0.01% 984
2026
Q2
$764 Buy
+14
New +$738 ﹤0.01% 1001
2025
Q1
– Sell
-1
Closed -$42 – 1082
2024
Q4
$39 Buy
+1
New +$47 ﹤0.01% 776

Other funds holding CRSP

Activest Wealth Management's CRSP Position: Q3 2026 in Review

Activest Wealth Management reduced its CRISPR Therapeutics (CRSP) stake by 79% in Q3 2026, selling an estimated $594 and leaving 3 shares worth $166. The position accounts for ﹤0.01% of the portfolio, ranked #984.

Activest Wealth Management first reported a position in CRSP in Q4 2024 and has held it in 3 quarters since. The position peaked at $764 in Q2 2026. 500 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Activest Wealth Management held 3 shares of CRISPR Therapeutics worth $166 as of Q3 2026.
  • Activest Wealth Management sold 11 CRISPR Therapeutics shares in Q3 2026, an estimated $594.
  • CRISPR Therapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q3 2026, its #984 holding.
  • Activest Wealth Management first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Activest Wealth Management's CRISPR Therapeutics position peaked at $764 in Q2 2026.
  • 500 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.